Year: 2022

Invitation to Q3 2022 Presentation 18 November BW Offshore will release its Q3 2022 results on Friday 18 November at 07:30 CET. The company will host a presentation of the financial results 09:00 (CET) the same day at Hotel Continental in Oslo, Norway. The presentation will be given by CEO Marco Beenen and CFO Ståle Andreassen. You can also follow the presentation via webcast with supporting slides, available on: BW Offshore Webcast Q3 2022 Please note that if you follow the webcast via the above URL, you will experience a 30 second delay compared to the main conference call. The web page works best in an updated browser – Chrome is recommended. For further information, please contact:Ståle Andreassen, CFO, +47 91 71 86 55Anders S. Platou, Head of Corporate Finance & Strategy, +47 99 50 47 40 IR@bwoffshore.com or www.bwoffshore.com About...

The “Black Soil” radioactive anomaly hosted in the overburden returned 0.93 wt.% U308, 1180 ppm Cobalt, 625 ppm Nickel and 196 ppm BoronFigure 1 Location of the “Black Soil” surface radioactive anomaly within GSUA. The background shows ground concentration of uranium from the airborne gamma-ray spectrometry survey (Ford et al., 2006).Photo 1 The “Black Soil” radioactive anomaly. Dimension of the Geiger Counter is 15 cm by 7.8 cm.CALGARY, Alberta, Nov. 14, 2022 (GLOBE NEWSWIRE) — Traction Uranium Corp. (CSE: TRAC) (OTC: TRCTF) (FRA: Z1K) (the “Company” or “Traction”) and Ugreenco Energy Corp. have received assay results from the SRC Geoanalytical Laboratories for till samples from the recently completed Phase 1 ground program at their Key Lake South (KLS) property (please refer to Traction’s news release dated September 27th,...

First mRNA manufacturing facility in Singapore will create regional manufacturing capacities in support of BioNTech’s growing pipeline of mRNA-based vaccines and therapeutics across Asia Pacific region for both clinical and commercial scale State-of-the art facility is expected to be fully operational in late 2023, and to create more than 100 jobs Acquisition marks the next step in BioNTech’s plans to establish a regional hub in the Asia Pacific RegionMAINZ, GERMANY, and SINGAPORE, November 14, 2022 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced its Singapore affiliate BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. had entered into an agreement with Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd. to acquire one of its GMP-certified manufacturing facilities. The acquisition is part of BioNTech’s...

— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint — — Overall survival, the other primary endpoint, was not statistically significant — — Safety findings consistent with fruquintinib known profile — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces initial results from FRUTIGA, a Phase III study of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (“GEJ”) adenocarcinoma. The trial was positive, having met one of the primary endpoints of statistically significant improvement in progression-free survival (“PFS”), which is clinically meaningful. The...

–   Data demonstrated that once-weekly TransCon CNP has the potential to meet patient and caregiver needs for a safe, effective, tolerable and convenient treatment –   The primary endpoint, annualized height velocity (AHV) at Week 52, demonstrated superiority of TransCon CNP at 100 µg/kg/week compared to placebo (p=0.0218) –   TransCon CNP was generally well tolerated with low frequency of injection site reactions; all 57 randomized children continued, with the longest treatment duration beyond two years –   Data showed robust and consistent results in prespecified analyses across age groups and dose levels, supporting continued development at the selected dose of 100 µg/kg/week –   Ascendis to host conference call and webcast Monday, November 14 at 8:00 a.m. Eastern time COPENHAGEN, Denmark, Nov. 14, 2022...